Beste Neurologen in Madrid - TOP -6 Ärzte

Dr. José Angel Obeso ist ein weltbekannter Neurologe mit über 40 Jahren Erfahrung und 30 Jahren Forschung im Bereich Bewegungsstörungen. Er ist der Gründer der ersten spezialisierten Gruppe für Bewegungsstörungen der spanischen Gesellschaft für Neurologie und hat die kontinuierliche dopaminerge Stimulation für die Parkinson-Krankheit entwickelt. Er hat über 350 Forschungsartikel verfasst und ist Mitglied der American Neurological Association und der International Parkinson and Movement Disorder Society.

Since 1998 he has been Director of the Epilepsy Unit at the Ruber International Hospital in Madrid, a pioneering centre for the diagnosis, medical and surgical treatment of epilepsy in children and adults.

More than 150 neurologists and neurophysiologists from Spain and Latin America have been trained here, and several of its students have successfully opened epilepsy centres in other public and private hospitals, both in Spain and abroad.

The program he directs has become a pioneer in Spain in the field of genetic diagnosis of complex epilepsies and advanced treatments such as drug repositioning, interstitial laser treatment, deep electrodes and gamma radiosurgery, which are used in patients with refractory epilepsy.

Dr. Antonio Gil-Nagel is a professor at the IE University, is an Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB) and is Director of the Epilepsy Department at the Francisco Vitoria University of Madrid.

He was a founding member of the European Epilepsy Research Network and the European Association for Epilepsy Monitoring. He is also active in international research projects such as EpiCare and the European Epilepsy Brain Bank and has held relevant positions in international institutions such as the International Bureau for Epilepsy (IBE), the International League Against Epilepsy (ILAE), the European Federation of Neurological Societies (EFNS) and the World Federation of Neurology (WFN).

Dr. Gil-Nagel has directed numerous clinical trials and research studies in the field of epilepsy, especially in orphan epilepsies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic and developmental encephalopathies. The Epilepsy Program he directs is an international benchmark in the development of pharmacological research. He has been the Principal Investigator of phase II and III clinical trials, including numerous clinical trials and non-pharmacological treatments (epilepsy surgery, electrical stimulation, ketogenic diet and gamma knife). His research is funded by European Union funds and the Public Innovation Agency of the Ministry of Science and Innovation of the Spanish Government. Their dedication to research and the development of new treatments allows them to accelerate the treatment of their patients with new treatments.

In addition to being a frequent speaker at national and international conferences, he has authored several books on epilepsy and electroencephalography and has numerous publications on epilepsy in journals such as Annals of Neurology, Brain, Epilepsy, European Journal of Neurology, Journal of Neurology, Nature Neurology, Neurology, and the New England Journal of Medicine, among others. He has authored 165 Scopus-indexed articles with 5,265 citations and an h-index of 35.

In 2021, his team received the Innovative Small and Medium Enterprise Award for the project on mesial temporal lobe epilepsy and encephalocele (Ministry of Science and Innovation, Spain), and in 2012, the Scientific Award from the Epilepsy Group of the Spanish Society of Neurology (SEN).

Education

• 1985 – Bachelor of Medicine and Surgery , Complutense University of Madrid.
• 1986-1989 – Specialization in Neurology , Hospital 12 de Octubre, Madrid.
• 1991–1993 – Epilepsy Specialist , Comprehensive Epilepsy Program, University of Minnesota, Minneapolis, USA.
• 1997 – Certification of the American Board of Clinical Neurophysiology .

Professional experience

• 1993–1995 – Associate Professor, Epilepsy Program, Department of Neurology, University of Minnesota, Minneapolis, USA.
• 1995–1998 – Associate Professor, Epilepsy Program, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, USA.
• Since 1998 – Director of the Epilepsy Program , Neurology Service, Ruber International Hospital, Madrid.
• 2014 – Defense of the dissertation on the topic: "Clinical and neurophysiological studies in the pre-surgical evaluation of epilepsy" , Complutense University of Madrid.
• 2022 – Deputy Head of the Neurology Service , Ruber Internacional International Hospital, Madrid.

Membership in professional societies

• Since 1991 – Member of the American Academy of Neurology (AAN).
• Since 1991 – Member of the American Epilepsy Society (AES).
• Since 1996 – Member of the American Society of Clinical Neurophysiology .
• Since 1988 – Member of the Spanish Society of Neurology .
• Since 2006 – Representative of Spain in the World Federation of Neurology (WFN).
• Since 2006 – Member of the editorial committee and the WFN web portal .
• Since 2008 – Director of the Epilepsy Group of the European Federation of Neurological Societies (EFNS).
• Since 2009 – Member of the EFNS Educational Courses Committee.
• 2007–2009 – Member of the EFNS Scientific Committee .
• 2007–2008 – Vice-President of the Scientific Committee of the 12th EFNS Congress , Madrid.
• 2004–2007 – Delegate of Spain to the EFNS .
• 2009 – Member of the Scientific Committee of the World Congress of Neurologists , Marrakech.

Outstanding Achievements

Dr. Hill-Nagel is a leading international figure in the field of epileptology, a recognized expert in the diagnosis and treatment of genetic epilepsy and the surgical approach to its correction. His distinguished professional career includes many years of experience in leading medical institutions in the United States and Europe, as well as active participation in international research and educational programs.

Dr. Hill-Nagel not only advances the science of neurology on a global level, but also successfully implements cutting-edge treatment methods, improving the lives of thousands of patients around the world.